HK1249452A1 - 免疫細胞捕獲裝置及其製備和使用方法 - Google Patents
免疫細胞捕獲裝置及其製備和使用方法Info
- Publication number
- HK1249452A1 HK1249452A1 HK18109141.9A HK18109141A HK1249452A1 HK 1249452 A1 HK1249452 A1 HK 1249452A1 HK 18109141 A HK18109141 A HK 18109141A HK 1249452 A1 HK1249452 A1 HK 1249452A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- making
- methods
- same
- immune cell
- cell trapping
- Prior art date
Links
- 210000002865 immune cell Anatomy 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/545—Synthetic resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/146—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/0004—Use of compounding ingredients, the chemical constitution of which is unknown, broadly defined, or irrelevant
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/04—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent
- C08J9/12—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent
- C08J9/122—Hydrogen, oxygen, CO2, nitrogen or noble gases
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/26—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a solid phase from a macromolecular composition or article, e.g. leaching out
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/438—Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2201/00—Foams characterised by the foaming process
- C08J2201/02—Foams characterised by the foaming process characterised by mechanical pre- or post-treatments
- C08J2201/032—Impregnation of a formed object with a gas
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2201/00—Foams characterised by the foaming process
- C08J2201/04—Foams characterised by the foaming process characterised by the elimination of a liquid or solid component, e.g. precipitation, leaching out, evaporation
- C08J2201/042—Elimination of an organic solid phase
- C08J2201/0422—Elimination of an organic solid phase containing oxygen atoms, e.g. saccharose
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2201/00—Foams characterised by the foaming process
- C08J2201/04—Foams characterised by the foaming process characterised by the elimination of a liquid or solid component, e.g. precipitation, leaching out, evaporation
- C08J2201/044—Elimination of an inorganic solid phase
- C08J2201/0444—Salts
- C08J2201/0446—Elimination of NaCl only
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2203/00—Foams characterized by the expanding agent
- C08J2203/06—CO2, N2 or noble gases
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2203/00—Foams characterized by the expanding agent
- C08J2203/08—Supercritical fluid
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2205/00—Foams characterised by their properties
- C08J2205/04—Foams characterised by their properties characterised by the foam pores
- C08J2205/044—Micropores, i.e. average diameter being between 0,1 micrometer and 0,1 millimeter
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2205/00—Foams characterised by their properties
- C08J2205/04—Foams characterised by their properties characterised by the foam pores
- C08J2205/05—Open cells, i.e. more than 50% of the pores are open
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2207/00—Foams characterised by their intended use
- C08J2207/10—Medical applications, e.g. biocompatible scaffolds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/04—Alginic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/12—Agar-agar; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2325/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring; Derivatives of such polymers
- C08J2325/02—Homopolymers or copolymers of hydrocarbons
- C08J2325/04—Homopolymers or copolymers of styrene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2329/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal, or ketal radical; Hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Derivatives of such polymer
- C08J2329/02—Homopolymers or copolymers of unsaturated alcohols
- C08J2329/04—Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2333/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
- C08J2333/04—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers esters
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2339/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Derivatives of such polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2339/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Derivatives of such polymers
- C08J2339/04—Homopolymers or copolymers of monomers containing heterocyclic rings having nitrogen as ring member
- C08J2339/06—Homopolymers or copolymers of N-vinyl-pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
- C08J2367/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2371/00—Characterised by the use of polyethers obtained by reactions forming an ether link in the main chain; Derivatives of such polymers
- C08J2371/02—Polyalkylene oxides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2385/00—Characterised by the use of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon; Derivatives of such polymers
- C08J2385/02—Characterised by the use of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon; Derivatives of such polymers containing phosphorus
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2389/00—Characterised by the use of proteins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2389/00—Characterised by the use of proteins; Derivatives thereof
- C08J2389/04—Products derived from waste materials, e.g. horn, hoof or hair
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562146205P | 2015-04-10 | 2015-04-10 | |
PCT/US2016/026617 WO2016164705A1 (en) | 2015-04-10 | 2016-04-08 | Immune cell trapping devices and methods for making and using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1249452A1 true HK1249452A1 (zh) | 2018-11-02 |
Family
ID=57072140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18109141.9A HK1249452A1 (zh) | 2015-04-10 | 2018-07-16 | 免疫細胞捕獲裝置及其製備和使用方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US11150242B2 (zh) |
EP (1) | EP3280464A4 (zh) |
JP (3) | JP7094533B2 (zh) |
CN (2) | CN114099793A (zh) |
HK (1) | HK1249452A1 (zh) |
WO (1) | WO2016164705A1 (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE534415T1 (de) | 2005-12-13 | 2011-12-15 | Harvard College | Gerüste zur zelltransplantation |
JP5690143B2 (ja) | 2008-02-13 | 2015-03-25 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 持続的細胞プログラミング装置 |
KR102155383B1 (ko) | 2010-10-06 | 2020-09-11 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 재료에 기초한 세포 치료를 위한 주사 가능한 기공 형성 하이드로겔 |
US9937249B2 (en) | 2012-04-16 | 2018-04-10 | President And Fellows Of Harvard College | Mesoporous silica compositions for modulating immune responses |
CN107073090A (zh) | 2014-04-30 | 2017-08-18 | 哈佛学院董事会 | 结合的疫苗装置和杀死癌细胞的方法 |
WO2016123573A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
CN115531609A (zh) | 2016-02-06 | 2022-12-30 | 哈佛学院校长同事会 | 重塑造血巢以重建免疫 |
MA45738A (fr) | 2016-07-13 | 2019-05-22 | Harvard College | Échafaudages mimétiques de cellules présentant l'antigène et procédés pour les préparer et les utiliser |
KR20240023684A (ko) | 2016-09-13 | 2024-02-22 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
GB201707048D0 (en) * | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
CN109459569A (zh) * | 2018-07-28 | 2019-03-12 | 南昌大学 | 一种免血样肿瘤早期监测的方法 |
CN118033116A (zh) * | 2018-08-15 | 2024-05-14 | 苏州尔生生物医药有限公司 | 用于抗原特异性t细胞含量检测的检测纳米颗粒、检测方法及试剂盒 |
EP3897764A4 (en) * | 2018-12-17 | 2022-07-27 | President and Fellows of Harvard College | BIOTECHNOLOGICALLY MANUFACTURED SCAFFOLDINGS FOR MODULATION OF THE IMMUNE SYSTEM AND USES THEREOF |
US11904000B2 (en) | 2019-05-06 | 2024-02-20 | Brown University | Compositions and methods to enhance cutaneous wound healing |
US20220354972A1 (en) * | 2019-06-21 | 2022-11-10 | North Carolina State University | In situ recruitment, reprogramming, and release of car-t cells |
CN110632308B (zh) * | 2019-10-25 | 2021-07-23 | 四川大学华西医院 | Casp8自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
CN113884682B (zh) * | 2021-04-30 | 2023-07-21 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 检测巨核细胞或血小板表面标志分子的产品在制备检测感染的产品中的用途 |
CN114870772B (zh) * | 2022-03-10 | 2024-07-12 | 上海威高医疗技术发展有限公司 | 一种脱细胞反应釜装置及脱细胞方法 |
Family Cites Families (239)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
GB9206504D0 (en) | 1992-03-25 | 1992-05-06 | Jevco Ltd | Heteromorphic sponges as wound implants |
JPH09506866A (ja) | 1993-12-14 | 1997-07-08 | ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | 医薬として活性のある物質の免疫療法のための放出制御 |
US5538733A (en) | 1994-07-07 | 1996-07-23 | Willmar Poultry Company, Inc. | Method of priming an immune response in a one-day old animal |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
ATE328890T1 (de) | 1994-07-15 | 2006-06-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
US6329499B1 (en) | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
US6251396B1 (en) | 1994-11-18 | 2001-06-26 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
EP0921816A4 (en) | 1996-03-28 | 2004-09-22 | Whitehead Biomedical Inst | CELLS WITH INCREASED OPSONINE CONTENT AND METHOD FOR REGULATING AN IMMUNE RESPONSE TO ANTIQUE |
IL118376A0 (en) | 1996-05-22 | 1996-09-12 | Univ Ben Gurion | Polysaccharide sponges for cell culture and transplantation |
US5885829A (en) | 1996-05-28 | 1999-03-23 | The Regents Of The University Of Michigan | Engineering oral tissues |
US6124128A (en) | 1996-08-16 | 2000-09-26 | The Regents Of The University Of California | Long wavelength engineered fluorescent proteins |
ES2317657T3 (es) | 1996-09-19 | 2009-04-16 | The Regents Of The University Of Michigan | Polimeros que contienen polisacaridos tales como alginatos o alginatos modificados. |
US5863551A (en) | 1996-10-16 | 1999-01-26 | Organogel Canada Ltee | Implantable polymer hydrogel for therapeutic uses |
GB2318577B (en) | 1996-10-28 | 2000-02-02 | Johnson & Johnson Medical | Solvent dried polysaccharide sponges |
GB2323282B (en) | 1997-03-17 | 2001-03-07 | Bristol Myers Squibb Co | Improvements relating to hygiene and medical products |
EP0991705B1 (en) | 1997-03-31 | 2003-09-10 | The Regents Of The University Of Michigan | Open pore biodegradable matrices |
JP4132089B2 (ja) | 1997-05-30 | 2008-08-13 | オステオバイオロジックス,インコーポレイテッド | 繊維強化多孔性生体分解性移植デバイス |
JP3990736B2 (ja) | 1997-08-21 | 2007-10-17 | タカラバイオ株式会社 | 制がん剤 |
JP4034036B2 (ja) | 1998-02-23 | 2008-01-16 | マサチューセッツ・インスティテュート・オブ・テクノロジー | 生分解性形状記憶ポリマー |
WO1999044583A2 (en) | 1998-03-02 | 1999-09-10 | Applied Vaccine Technologies Corp. | Methods and devices for modulating the immune response |
DE69935507T2 (de) | 1998-04-03 | 2007-12-06 | University Of Iowa Research Foundation | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
US7427602B1 (en) | 1998-05-13 | 2008-09-23 | The Regents Of The University Of Michigan | Sustained DNA delivery from structural matrices |
US7244714B1 (en) | 1998-06-12 | 2007-07-17 | Aradigm Corporation | Methods of delivering aerosolized polynucleotides to the respiratory tract |
FR2780730B1 (fr) | 1998-07-01 | 2000-10-13 | Corneal Ind | Compositions biphasiques injectables, notamment utiles en chirurgies reparatrice et esthetique |
DE69924615T3 (de) | 1998-07-30 | 2011-05-05 | The Government Of The United States Of America, Represented By The Department Of Health & Human Services, National Institute Of Health, Office Of Technology Transfer | Thymosin beta 4 stimuliert wundheilung |
AU6419899A (en) | 1998-10-09 | 2000-05-01 | Regents Of The University Of Michigan, The | Hydrogels and water soluble polymeric carriers for drug delivery |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
US6974698B1 (en) | 1999-01-15 | 2005-12-13 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for delivering biologically active molecules into cells |
EP2286792A1 (en) | 1999-02-26 | 2011-02-23 | Novartis Vaccines and Diagnostics, Inc. | Microemulsions with an adsorbent surface, comprising a microdroplet emulsion |
CA2370063C (en) | 1999-03-19 | 2012-10-02 | The Regents Of The University Of Michigan | Mineralization and cellular patterning on biomaterial surfaces |
US6767928B1 (en) | 1999-03-19 | 2004-07-27 | The Regents Of The University Of Michigan | Mineralization and biological modification of biomaterial surfaces |
EP1163019B1 (en) | 1999-03-25 | 2007-10-24 | Metabolix, Inc. | Medical devices and applications of polyhydroxyalkanoate polymers |
CA2364570A1 (en) | 1999-04-09 | 2000-10-19 | The Regents Of The University Of Michigan | Preparing porous hydrogel products |
AU782297B2 (en) | 1999-06-30 | 2005-07-14 | Ethicon Inc. | Porous tissue scaffoldings for the repair or regeneration of tissue |
US8084258B2 (en) | 1999-07-12 | 2011-12-27 | University Of Basel | Manipulation of tissue of organ type using the notch pathway |
US6596296B1 (en) | 1999-08-06 | 2003-07-22 | Board Of Regents, The University Of Texas System | Drug releasing biodegradable fiber implant |
US7015205B1 (en) | 1999-10-18 | 2006-03-21 | St. Vincent's Hospital And Medical Center Of New York | Melanoma vaccine and methods of making and using same |
AU1622801A (en) | 1999-11-18 | 2001-05-30 | Regents Of The University Of Michigan, The | Sustained drug delivery from structural matrices |
US6682754B2 (en) | 1999-11-24 | 2004-01-27 | Willmar Poultry Company, Inc. | Ovo delivery of an immunogen containing implant |
US6790840B1 (en) | 1999-11-26 | 2004-09-14 | The Regents Of The University Of Michigan | Reversibly cross-linked hydrogels |
US20020098167A1 (en) | 2000-07-31 | 2002-07-25 | Piero Anversa | Methods and compositions for the repair and/or regeneration of damaged myocardium |
AU2001286613A1 (en) | 2000-08-21 | 2002-03-04 | Rice University | Tissue engineering scaffolds promoting matrix protein production |
ATE475887T1 (de) | 2000-09-09 | 2010-08-15 | Univ New York State Res Found | Verfahren und zusammensetzungen zur isolierung von metastatischen krebszellen und anwendung zur messung des metastatischen potentials eines krebses |
US6748954B2 (en) | 2000-10-27 | 2004-06-15 | The Regents Of The University Of Michigan | Drug release from polymer matrices through mechanical stimulation |
WO2002040071A1 (fr) | 2000-11-14 | 2002-05-23 | Osteogenesis Co., Ltd. | Compositions stimulant la formation d'un os ou d'un parodonte et injections pour la formation d'un os ou d'un parodonte |
WO2002041913A1 (en) | 2000-11-27 | 2002-05-30 | Jens Christian Jensenius | Collectins as adjuvants |
US20070198739A1 (en) | 2001-01-19 | 2007-08-23 | Streamworks Technologies, Inc. | System and method for routing media |
JP2004520043A (ja) | 2001-01-24 | 2004-07-08 | シェーリング コーポレイション | 免疫応答のアジュバントとしてのケモカイン |
US7029697B2 (en) | 2001-02-14 | 2006-04-18 | Northwestern University | Controlled surface-associated delivery of genes and oligonucleotides |
CA2439400A1 (en) | 2001-02-26 | 2002-09-06 | The Regents Of The University Of California | Non-oligomerizing tandem fluorescent proteins |
JP2002263981A (ja) | 2001-03-14 | 2002-09-17 | Murata Mach Ltd | 板材吸着持ち上げ装置の吸着制御装置 |
US20020131953A1 (en) | 2001-03-14 | 2002-09-19 | Ut Southwestern Medical Center | In situ langerhans cell vaccine |
US6656488B2 (en) | 2001-04-11 | 2003-12-02 | Ethicon Endo-Surgery, Inc. | Bioabsorbable bag containing bioabsorbable materials of different bioabsorption rates for tissue engineering |
US20030082806A1 (en) | 2001-04-27 | 2003-05-01 | Xcyte Therapies, Inc. | Maturation of antigen-presenting cells using activated T cells |
US20030118630A1 (en) | 2001-12-07 | 2003-06-26 | Anthony Cerami | Immune modulation device for use in animals |
JP4866535B2 (ja) * | 2001-05-11 | 2012-02-01 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 動物で用いるに適した免疫調節用デバイス |
CA2450720A1 (en) | 2001-06-13 | 2002-12-19 | Massachusetts Institute Of Technology | In vivo bioreactors |
US7297343B2 (en) | 2001-07-31 | 2007-11-20 | Biosurface Engineering Technologies, Inc. | Bioactive medical films |
AU2002361468A1 (en) | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
CA2412012C (en) | 2001-11-20 | 2011-08-02 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage |
JP2005514105A (ja) | 2001-12-31 | 2005-05-19 | アレス ラボラトリーズ エルエルシー | 出血を制御するための止血組成物および方法 |
US7575759B2 (en) | 2002-01-02 | 2009-08-18 | The Regents Of The University Of Michigan | Tissue engineering scaffolds |
US20070026518A1 (en) | 2005-03-29 | 2007-02-01 | The Regents Of The University Of California | Controlling stem cell destiny with tunable matrices |
US20080233181A1 (en) | 2002-04-12 | 2008-09-25 | Nagy Jon O | Nanoparticle adjuvants for sub-unit vaccines |
US6811777B2 (en) | 2002-04-13 | 2004-11-02 | Allan Mishra | Compositions and minimally invasive methods for treating incomplete connective tissue repair |
AU2003219383B2 (en) | 2002-04-22 | 2010-08-26 | Bioniche Life Sciences Inc. | Oligonucleotide compositions and their use for the modulation of immune responses |
US6960617B2 (en) | 2002-04-22 | 2005-11-01 | Purdue Research Foundation | Hydrogels having enhanced elasticity and mechanical strength properties |
WO2003096972A2 (en) | 2002-05-13 | 2003-11-27 | Massachusetts Institute Of Technology | Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof |
AUPS312602A0 (en) | 2002-06-21 | 2002-07-18 | James Cook University | Organ arrest, protection, preservation and recovery |
US7332160B2 (en) | 2002-07-12 | 2008-02-19 | Boston Scientific Scimed, Inc. | Medical device and method for tissue removal and repair |
CN103073620B (zh) | 2002-09-12 | 2014-12-10 | 肿瘤疗法科学股份有限公司 | Kdr肽和包括该肽的疫苗 |
US20040136968A1 (en) | 2002-09-27 | 2004-07-15 | Verigen Ag | Autologous cells on a support matrix for tissue repair |
US20040063206A1 (en) | 2002-09-30 | 2004-04-01 | Rowley Jon A. | Programmable scaffold and method for making and using the same |
AU2003272805A1 (en) | 2002-10-01 | 2004-04-23 | Peter K. Law | Bioactive implants |
JP2004159849A (ja) | 2002-11-12 | 2004-06-10 | National Institute Of Advanced Industrial & Technology | 細胞接着性生体吸収材料、人工血管およびそれらの製造方法 |
JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
US8940292B2 (en) | 2003-01-28 | 2015-01-27 | Wake Forest University Health Sciences | Enhancement of angiogenesis to grafts using cells engineered to produce growth factors |
SE0301109D0 (sv) | 2003-04-14 | 2003-04-14 | Mallen Huang | Nucleotide vaccine composition |
DK1620140T3 (da) | 2003-05-05 | 2013-12-09 | Univ Ben Gurion | Injicerbare tværbundne polymere præparater samt deres anvendelse |
EP1475434A1 (en) | 2003-05-09 | 2004-11-10 | Oncoscience AG | Method for storing tumor cells |
JP2007528848A (ja) | 2003-07-09 | 2007-10-18 | ヴァックスデザイン・コーポレーション | ワクチン接種ノードを用いるプログラムされた免疫応答 |
US20060264380A1 (en) | 2003-07-21 | 2006-11-23 | Mats Hellstrom | Compounds and Methods for Promoting Angiogenesis |
GB0317999D0 (en) | 2003-07-31 | 2003-09-03 | Univ Liege | Improvements in or relating to drug delivery systems |
EP1651259A4 (en) | 2003-07-31 | 2008-05-28 | Endacea Inc | METHOD AND COMPOSITIONS FOR PRODUCING ANTIGENIC ANSWERS |
EP1664168B1 (en) | 2003-08-29 | 2008-12-03 | Mayo Foundation for Medical Education and Research | Hydrogel porogens for fabricating biodegradable scaffolds |
JP5097400B2 (ja) | 2003-09-03 | 2012-12-12 | デンドリセラピューティクス、インク. | 複合ワクチン |
GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
CA2542332C (en) | 2003-10-16 | 2013-03-12 | Stephen John Ralph | Immunomodulating compositions and uses therefor |
EP1689289B1 (en) | 2003-11-07 | 2016-12-21 | Carnegie Mellon University | Robot for minimally invasive interventions |
CA2448995A1 (en) | 2003-11-12 | 2005-05-12 | James Keenan | Device and method for attracting diseased cells and foreign substances |
JP2005160669A (ja) | 2003-12-02 | 2005-06-23 | Olympus Corp | 生体組織補填体の製造方法 |
JP2005170816A (ja) | 2003-12-09 | 2005-06-30 | Naoki Ishiguro | 軟骨修復用材料、およびその製造方法 |
EP1697511A4 (en) | 2003-12-11 | 2007-11-21 | Vaxdesign Corp | IMMUNOTHERAPY COMPOSITIONS, METHODS FOR PREPARING AND USING THE SAME |
US11395865B2 (en) | 2004-02-09 | 2022-07-26 | DePuy Synthes Products, Inc. | Scaffolds with viable tissue |
US7192693B2 (en) | 2004-02-24 | 2007-03-20 | University Of Washington | Methods for photopatterning hydrogels |
WO2005087238A2 (en) | 2004-03-15 | 2005-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
CA2564512C (en) | 2004-04-28 | 2014-03-18 | Vaxdesign Corporation | Artificial immune system: methods for making and use |
WO2006080946A2 (en) | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
WO2007001332A2 (en) | 2004-08-04 | 2007-01-04 | University Of Massachusetts | Anti-pathogen immunoadhesins |
WO2006039045A2 (en) | 2004-09-01 | 2006-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
US7235592B2 (en) | 2004-10-12 | 2007-06-26 | Zimmer Gmbh | PVA hydrogel |
BRPI0515973B8 (pt) | 2004-10-12 | 2021-07-27 | Fmc Biopolymer As | kit para produzir um gel de alginato, composição para preparar um gel e uso |
WO2007042554A2 (en) | 2005-10-12 | 2007-04-19 | Cancer Research Technology Ltd. | Methods and compositions for treating immune disorders |
US7999161B2 (en) | 2005-01-22 | 2011-08-16 | Alexander Oraevsky | Laser-activated nanothermolysis of cells |
US7569850B2 (en) | 2005-01-24 | 2009-08-04 | Lawrence Livermore National Security, Llc | Lipid bilayers on nano-templates |
WO2006102530A1 (en) | 2005-03-23 | 2006-09-28 | Mayo Foundation For Medical Education And Research | Photocrosslinkable oligo(poly (ethylene glycol) fumarate) hydrogels for cell and drug delivery |
EP1712238A1 (en) | 2005-04-11 | 2006-10-18 | Institut Gustave Roussy | Anthracyclin induced immunogenic dead or dying cells composition |
US20070003595A1 (en) | 2005-04-19 | 2007-01-04 | Shaopeng Wang | Three dimensional micro-environments and methods of making and using same |
US8828433B2 (en) | 2005-04-19 | 2014-09-09 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
WO2006116423A2 (en) | 2005-04-26 | 2006-11-02 | Eisai Co., Ltd | Compositions and methods for cancer immunotherapy |
WO2006119619A1 (en) | 2005-05-06 | 2006-11-16 | Replicor Inc. | Oligonucleotides inhibiting cell proliferation |
ITPI20050071A1 (it) | 2005-06-20 | 2006-12-21 | Giuseppe Calvosa | Composizione biocompatibile per la sostituzione/rigenerazione di tessuti |
US7645742B2 (en) | 2005-06-22 | 2010-01-12 | Advocare International, L.P. | Composition for enhancing cellular energy |
CN1302050C (zh) | 2005-07-07 | 2007-02-28 | 复旦大学 | 一种互穿网络聚合物超多孔水凝胶及其制备方法和应用 |
US20090017096A1 (en) | 2005-08-15 | 2009-01-15 | Anthony Lowman | Porous non-biodegradable hydrogel admixed with a chemoattractant for tissue replacement |
BRPI0503817A (pt) | 2005-09-12 | 2007-05-15 | Cristalia Prod Quimicos Farm | complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada |
EP2340847A3 (en) | 2005-09-23 | 2016-11-09 | Cellerix, S.A. | Cell populations having immunoregulatory activity, method for isolation and uses |
US20070081972A1 (en) | 2005-09-30 | 2007-04-12 | The University Of Iowa Research Foundation | Polymer-based delivery system for immunotherapy of cancer |
US8029575B2 (en) | 2005-10-25 | 2011-10-04 | Globus Medical, Inc. | Porous and nonporous materials for tissue grafting and repair |
US20070116680A1 (en) | 2005-11-18 | 2007-05-24 | Rensselaer Polytechnic Institute | Stem cells within gel microenvironments |
US8748126B2 (en) | 2005-11-29 | 2014-06-10 | Actogenix N.V. | Induction of mucosal tolerance to antigens |
KR100687281B1 (ko) | 2005-11-30 | 2007-02-27 | 한국과학기술연구원 | 생리 활성 물질이 결합된 조직 재생용 주입형 온도 감응성플루로닉 유도체 하이드로겔 및 이의 제조 방법 |
WO2007064857A2 (en) | 2005-12-01 | 2007-06-07 | Pronai Therapeutics, Inc. | Amphoteric liposome formulation |
AU2015264807A1 (en) | 2005-12-13 | 2015-12-17 | President And Fellows Of Harvard College | Scaffolds for Cell Transplantation |
ATE534415T1 (de) | 2005-12-13 | 2011-12-15 | Harvard College | Gerüste zur zelltransplantation |
EP1960008A2 (en) | 2005-12-14 | 2008-08-27 | Scil Technology GmbH | A moldable biomaterial for bone regeneration |
EP1806395A1 (en) | 2006-01-06 | 2007-07-11 | Stichting Sanquin Bloedvoorziening | Maturation of dendritic cells |
US7615556B2 (en) | 2006-01-27 | 2009-11-10 | Bristol-Myers Squibb Company | Piperazinyl derivatives as modulators of chemokine receptor activity |
US20070178159A1 (en) | 2006-01-30 | 2007-08-02 | Alza Corporation | In-Situ Forming Porous Scaffold |
CA2676601A1 (en) | 2006-01-31 | 2007-08-09 | Medivas, Llc | Vaccine delivery compositions and methods of use |
US20100015709A1 (en) | 2006-02-10 | 2010-01-21 | Trustees Of The University Of Pennsylvania | Regulating Stem Cell Differentiation By Controlling 2D and 3D Matrix Elasticity |
US20070190646A1 (en) | 2006-02-10 | 2007-08-16 | The Trustees Of The University Of Pennsylvania | Regulating stem cell differentiation by controlling matrix elasticity |
JP2009528080A (ja) | 2006-02-27 | 2009-08-06 | エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ | 硬化性骨セメント |
US9456860B2 (en) | 2006-03-14 | 2016-10-04 | Kci Licensing, Inc. | Bioresorbable foaming tissue dressing |
GB0605521D0 (en) | 2006-03-18 | 2006-04-26 | Isis Innovation | Adjuvant |
US20090297579A1 (en) | 2006-06-01 | 2009-12-03 | Massachusetts Institute Of Technology | Control of Cells and Cell Multipotentiality in Three Dimensional Matrices |
WO2007146319A2 (en) | 2006-06-13 | 2007-12-21 | Symphony Medical, Inc. | Methods and apparatus for using polymer-based beads and hydrogels for cardiac applications |
US20070298067A1 (en) | 2006-06-22 | 2007-12-27 | Boston Scientific Scimed, Inc. | Control release drug coating for medical devices |
WO2007150020A1 (en) | 2006-06-23 | 2007-12-27 | Simon Paul M | Targeted immune conjugates |
US8535719B2 (en) | 2006-07-07 | 2013-09-17 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Biohybrid elastomeric scaffolds and methods of use thereof |
US7993918B2 (en) | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
KR100802139B1 (ko) | 2006-08-08 | 2008-02-11 | 한국생명공학연구원 | 자성 나노입자를 함유하는 골드 나노케이지 |
KR100818708B1 (ko) | 2006-08-18 | 2008-04-01 | 주식회사 하이닉스반도체 | 표면 세정을 포함하는 반도체소자 제조방법 |
ITMI20061726A1 (it) | 2006-09-11 | 2008-03-12 | Fidia Farmaceutici | Derivati crosslinkati a base di acido ialuronico reticolato via click chemistry |
CA2663722C (en) | 2006-09-21 | 2014-12-09 | Purdue Research Foundation | Collagen preparation and method of isolation |
JP2010505883A (ja) | 2006-10-12 | 2010-02-25 | ザ ユニバーシティー オブ クイーンズランド | 免疫応答を調節するための組成物および方法 |
WO2008060475A2 (en) | 2006-11-09 | 2008-05-22 | Kci Licensing Inc. | Porous bioresorbable linked dressing comprising microspheres and methods of making same |
WO2008086486A1 (en) | 2007-01-10 | 2008-07-17 | The Regents Of The University Of Michigan | Porous objects having immobilized encapsulated biomolecules |
JP5650406B2 (ja) | 2007-03-07 | 2015-01-07 | ユーティーアイ リミテッド パートナーシップ | 自己免疫状態の予防および治療のための組成物および方法 |
WO2008114149A2 (en) | 2007-03-21 | 2008-09-25 | Id Biomedical Corporation Of Quebec | Chimeric antigens |
US8501905B2 (en) | 2007-03-22 | 2013-08-06 | The Regents Of The University Of California | Synthetic cell platforms and methods of use thereof |
EP1975230A1 (en) | 2007-03-30 | 2008-10-01 | Capsulution Nanoscience AG | Method for forming glucose sensing micro-particles, use of micro-particles, and kit |
US8188058B2 (en) | 2007-04-19 | 2012-05-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders |
JP2010529078A (ja) | 2007-06-05 | 2010-08-26 | ノバルティス アーゲー | 成熟樹状細胞における免疫寛容誘発表現型の誘導 |
JP2010531138A (ja) | 2007-06-13 | 2010-09-24 | ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー | 制御性t細胞ならびに同製造および使用方法 |
WO2009002401A2 (en) | 2007-06-21 | 2008-12-31 | President And Fellows Of Harvard College | Scaffolds for cell collection or elimination |
ES2580161T3 (es) | 2007-06-29 | 2016-08-19 | Makoto Funaki | Sistemas de geles blandos en la modulación del desarrollo de células madre |
KR20100063048A (ko) | 2007-07-31 | 2010-06-10 | 더 존스 홉킨스 유니버시티 | 신생물성 또는 감염성 장애의 면역예방 또는 면역치료를 위한 폴리펩티드-핵산 접합체 |
GB0716264D0 (en) | 2007-08-21 | 2007-09-26 | Isis Innovation | Bilayers |
US20090192079A1 (en) | 2007-10-09 | 2009-07-30 | Genzyme Corporation | Prolonged delivery of heparin-binding growth factors from heparin-derivatized collagen |
KR100900837B1 (ko) | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물 |
EP2072617A1 (en) | 2007-12-12 | 2009-06-24 | Trimed Biotech GmbH | Method for producing dendritic cells |
DE102008008522A1 (de) | 2008-02-11 | 2009-08-13 | Magforce Nanotechnologies Ag | Implantierbare Nanopartikel-enthaltende Produkte |
WO2011063336A2 (en) | 2009-11-20 | 2011-05-26 | President And Fellows Of Harvard College | Secondary site of antigen stimulation for therapeutic vaccination |
JP5690143B2 (ja) | 2008-02-13 | 2015-03-25 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 持続的細胞プログラミング装置 |
US9370558B2 (en) * | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
WO2009117721A1 (en) | 2008-03-21 | 2009-09-24 | 3D Biotek, Llc | Hybrid biomedical device fabricated from biomaterials and coated with a cell culture derived ecm coating |
CN102170903B (zh) * | 2008-05-02 | 2016-04-06 | 亮点医疗有限公司 | 用于刺激免疫反应的产品和方法 |
US9012399B2 (en) | 2008-05-30 | 2015-04-21 | President And Fellows Of Harvard College | Controlled release of growth factors and signaling molecules for promoting angiogenesis |
WO2009155583A1 (en) | 2008-06-19 | 2009-12-23 | The Trustees Of The University Of Pennsylvania | Biomaterials for tissue replacement |
EA023148B1 (ru) | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
US8889124B2 (en) | 2008-09-25 | 2014-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Tolerogenic populations of dendritic cells |
US8940331B2 (en) | 2008-11-22 | 2015-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrogels, methods of making hydrogels, methods of using hydrogels, and methods of isolating, trapping, attracting, and/or killing cancer cells |
KR101132732B1 (ko) | 2008-11-26 | 2012-04-06 | 한국과학기술연구원 | 인 시튜 조직재생용 지능형 다공성 생분해 고분자 지지체 및 이의 제조방법 |
US8273373B2 (en) | 2008-12-30 | 2012-09-25 | Case Western Reserve University | Photocrosslinked biodegradable hydrogel |
EP2385980B1 (en) | 2009-01-08 | 2018-04-18 | Albert Einstein College of Medicine, Inc. | Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof |
JP2010227012A (ja) | 2009-03-27 | 2010-10-14 | Seiko Epson Corp | がん細胞捕捉デバイス |
WO2010120749A2 (en) | 2009-04-13 | 2010-10-21 | President And Fellow Of Harvard College | Harnessing cell dynamics to engineer materials |
US8551749B2 (en) | 2009-04-23 | 2013-10-08 | The Invention Science Fund I, Llc | Device including bone cage and method for treatment of disease in a subject |
EP2461828B1 (en) | 2009-07-31 | 2017-06-21 | President and Fellows of Harvard College | Programming of cells for tolerogenic therapies |
CN101655611B (zh) | 2009-09-11 | 2011-06-08 | 中国科学院长春应用化学研究所 | 一种具有双层杂化结构的反蛋白石水凝胶光子晶体的制备方法 |
CA2776954A1 (en) | 2009-10-09 | 2011-04-14 | Anaphore, Inc. | Combinatorial libraries based on c-type lectin domain |
JP2013507124A (ja) | 2009-10-09 | 2013-03-04 | アナフォア インコーポレイテッド | Il−23rを結合するポリペプチド |
US20110207166A1 (en) | 2009-11-06 | 2011-08-25 | Sarah Rivkah Vaiselbuh | Human bone marrow microenvironments and uses thereof |
CN102656119B (zh) | 2009-12-18 | 2015-11-25 | 花王株式会社 | 介孔二氧化硅颗粒的制造方法 |
JP5603063B2 (ja) | 2009-12-21 | 2014-10-08 | 花王株式会社 | 複合シリカ粒子の製造方法 |
US9150631B2 (en) | 2010-01-19 | 2015-10-06 | President And Fellows Of Harvard College | Engineered opsonin for pathogen detection and treatment |
AU2011217780B2 (en) | 2010-02-22 | 2016-02-11 | Incredible Foods, Inc. | Enclosing materials in natural transport systems |
CN102869446B (zh) | 2010-03-02 | 2016-03-30 | 阿卜杜拉国王科技大学 | 高比表面积纤维二氧化硅纳米颗粒 |
EP2543636A4 (en) | 2010-03-04 | 2015-12-09 | Tokyo Metro Ind Tech Res Inst | PROCESS FOR PRODUCING POROUS SILICA, AND POROUS SILICA |
US9610328B2 (en) | 2010-03-05 | 2017-04-04 | President And Fellows Of Harvard College | Enhancement of skeletal muscle stem cell engraftment by dual delivery of VEGF and IGF-1 |
EP2547371A1 (en) | 2010-03-15 | 2013-01-23 | Ferrosan Medical Devices A/S | A method for promotion of hemostasis and/or wound healing |
US20110256184A1 (en) | 2010-04-14 | 2011-10-20 | Battelle Memorial Institute | Non-ordered Mesoporous Silica Structure for Biomolecule Loading and Release |
US20110300186A1 (en) | 2010-04-14 | 2011-12-08 | Battelle Memorial Institute | Functionalized Nano- and Micro-materials for Medical Therapies |
KR20130108983A (ko) | 2010-05-26 | 2013-10-07 | 셀렉타 바이오사이언시즈, 인크. | 커플링되지 않은 애주번트를 갖는 나노담체 조성물 |
GB201009273D0 (en) | 2010-06-03 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel vaccine |
EP2585053A4 (en) | 2010-06-25 | 2014-02-26 | Harvard College | COMMON RELEASE OF STIMULATING AND HEMMING FACTORS FOR THE PRODUCTION OF TEMPORARY STABILIZED AND SPATULARLY LIMITED ZONES |
WO2012009611A2 (en) | 2010-07-16 | 2012-01-19 | The Johns Hopkins University | Methods and compositions for cancer immunotherapy |
US11273250B2 (en) | 2010-08-04 | 2022-03-15 | Georgia Tech Research Corporation | Devices, systems, and methods for excavating cancer cells |
KR102155383B1 (ko) | 2010-10-06 | 2020-09-11 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 재료에 기초한 세포 치료를 위한 주사 가능한 기공 형성 하이드로겔 |
US9603894B2 (en) | 2010-11-08 | 2017-03-28 | President And Fellows Of Harvard College | Materials presenting notch signaling molecules to control cell behavior |
US10647959B2 (en) | 2011-04-27 | 2020-05-12 | President And Fellows Of Harvard College | Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation |
ES2685327T3 (es) | 2011-04-28 | 2018-10-08 | President And Fellows Of Harvard College | Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva |
US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
CA2834532A1 (en) | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses |
US9486512B2 (en) | 2011-06-03 | 2016-11-08 | President And Fellows Of Harvard College | In situ antigen-generating cancer vaccine |
BR112013033182A2 (pt) | 2011-06-24 | 2016-09-06 | Arqule Inc | compostos imidazopiridinil-aminopiridina substituída |
EP2734843A2 (en) | 2011-07-18 | 2014-05-28 | President and Fellows of Harvard College | Engineered microbe-targeting molecules and uses thereof |
US20130145488A1 (en) | 2011-12-06 | 2013-06-06 | Iowa State University Research Foundation, Inc. | Mesoporous silica nanoparticles suitable for co-delivery |
CA2861107A1 (en) * | 2012-01-13 | 2013-07-18 | President And Fellows Of Harvard College | Controlled delivery of tlr agonists in structural polymeric devices |
EP2825156B1 (en) | 2012-03-16 | 2017-07-26 | Merck Patent GmbH | Targeting aminoacid lipids |
US9937249B2 (en) | 2012-04-16 | 2018-04-10 | President And Fellows Of Harvard College | Mesoporous silica compositions for modulating immune responses |
MX349035B (es) | 2012-05-17 | 2017-07-07 | Extend Biosciences Inc | Portadores para el suministro mejorado de farmaco. |
MX2014015830A (es) | 2012-06-21 | 2015-03-05 | Compugen Ltd | Anticuerpos lsr y usos de los mismos para el tratamiento de cancer. |
US20140072510A1 (en) * | 2012-09-13 | 2014-03-13 | Northwestern University | Synthetic Scaffolds for Metastasis Detection |
EP2908862B1 (en) | 2012-10-20 | 2018-03-07 | Board Of Regents, The University Of Texas System | Cancer cell trap |
WO2014160499A2 (en) | 2013-03-13 | 2014-10-02 | Creatics Llc | Methods and compositions for detecting pancreatic cancer |
CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
EP3010522B1 (en) | 2013-05-21 | 2021-01-20 | President and Fellows of Harvard College | Engineered heme-binding compositions and uses thereof |
WO2014190229A1 (en) | 2013-05-24 | 2014-11-27 | President And Fellows Of Harvard College | Methods of isolating microorganisms and uses thereof |
EP3062779B1 (en) | 2013-11-01 | 2024-06-12 | Yale University | Modular particles for immunotherapy |
EP3125960B1 (en) | 2014-04-04 | 2020-06-03 | President and Fellows of Harvard College | Click-crosslinked hydrogels and methods of use |
CN107073090A (zh) * | 2014-04-30 | 2017-08-18 | 哈佛学院董事会 | 结合的疫苗装置和杀死癌细胞的方法 |
US11065362B2 (en) | 2014-06-12 | 2021-07-20 | President And Fellows Of Harvard College | Viscoelastic hydrogels with fast stress relaxation |
WO2016004068A1 (en) | 2014-06-30 | 2016-01-07 | Jae-Won Shin | Hydrogel compositions comprising encapsulated cells and methods of use thereof |
WO2016123573A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
WO2016161372A1 (en) | 2015-04-01 | 2016-10-06 | President And Fellows Of Harvard College | Immunoconjugates for programming or reprogramming of cells |
US10435457B2 (en) | 2015-08-06 | 2019-10-08 | President And Fellows Of Harvard College | Microbe-binding molecules and uses thereof |
CN115531609A (zh) | 2016-02-06 | 2022-12-30 | 哈佛学院校长同事会 | 重塑造血巢以重建免疫 |
CN108697778B (zh) | 2016-02-16 | 2023-10-03 | 哈佛学院院长等 | 病原体疫苗及其生产和使用方法 |
MA45738A (fr) | 2016-07-13 | 2019-05-22 | Harvard College | Échafaudages mimétiques de cellules présentant l'antigène et procédés pour les préparer et les utiliser |
IL264557B2 (en) | 2016-08-02 | 2024-01-01 | Harvard College | Biological agents for regulating immune responses |
-
2016
- 2016-04-08 US US15/564,905 patent/US11150242B2/en active Active
- 2016-04-08 CN CN202111373327.XA patent/CN114099793A/zh active Pending
- 2016-04-08 WO PCT/US2016/026617 patent/WO2016164705A1/en active Application Filing
- 2016-04-08 EP EP16777342.3A patent/EP3280464A4/en active Pending
- 2016-04-08 JP JP2017552479A patent/JP7094533B2/ja active Active
- 2016-04-08 CN CN201680027983.5A patent/CN107708756A/zh active Pending
-
2018
- 2018-07-16 HK HK18109141.9A patent/HK1249452A1/zh unknown
-
2021
- 2021-01-04 JP JP2021000075A patent/JP2021048879A/ja active Pending
- 2021-10-14 US US17/501,821 patent/US20220107308A1/en not_active Abandoned
-
2023
- 2023-09-19 JP JP2023151662A patent/JP2023166584A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220107308A1 (en) | 2022-04-07 |
US20180164298A1 (en) | 2018-06-14 |
CN114099793A (zh) | 2022-03-01 |
JP7094533B2 (ja) | 2022-07-04 |
JP2021048879A (ja) | 2021-04-01 |
JP2018510887A (ja) | 2018-04-19 |
US11150242B2 (en) | 2021-10-19 |
CN107708756A (zh) | 2018-02-16 |
WO2016164705A1 (en) | 2016-10-13 |
EP3280464A1 (en) | 2018-02-14 |
EP3280464A4 (en) | 2018-09-26 |
JP2023166584A (ja) | 2023-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1249452A1 (zh) | 免疫細胞捕獲裝置及其製備和使用方法 | |
HK1243104A1 (zh) | 抗fgfr2/3抗體及其使用方法 | |
IL267129A (en) | New T-cell receptors and immunotherapy using them | |
HK1245613A1 (zh) | 多重擊發的固定裝置及其使用和製造方法 | |
LT3500593T (lt) | T ląstelių receptoriai ir imuninė terapija juos naudojant | |
PL3308414T3 (pl) | Urządzenie fotowoltaiczne | |
SG11201708481TA (en) | Filtering devices and filtering methods | |
ZA201900664B (en) | T cell receptors and immune therapy using the same | |
IL256146A (en) | Photovoltaic device and components | |
ZA202105220B (en) | Cell penetrating antibodies | |
PL3381059T3 (pl) | Urządzenie fotowoltaiczne | |
TWI562334B (en) | Semiconductor device and methods for forming the same | |
IL259202A (en) | Modified immune cells and their use | |
ZA201606325B (en) | Sports field structure and method for forming the same | |
TWI562362B (en) | Semiconductor device structure and method for forming the same | |
SG11201703487TA (en) | Cell isolation method and cell trapping filter | |
GB201513366D0 (en) | Photovoltaic device | |
SG11201706058VA (en) | Gel, method of forming the same, photovoltaic device and method of forming the same | |
GB2560211B (en) | Methods and devices | |
TWI562309B (en) | Semiconductor structure and method for fabricating the same | |
SG11202000811RA (en) | Methods for activating immune cells | |
GB201517786D0 (en) | Methods and materials | |
SG11201706586SA (en) | Column-pile connecting method and connecting structure | |
GB201513590D0 (en) | Devices and methods | |
IL264855B1 (en) | T-cell receptors and immunotherapy using them |